Plain-English translation of NCT03439280 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple myeloma research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial tested a new medication called TAK-079 to see if it could help people with multiple myeloma that had stopped responding to other treatments. The researchers gave the medication as injections under the skin and studied whether it was safe, tolerable, and effective at slowing or stopping the cancer's growth.
Multiple myeloma is a blood cancer that can become resistant to standard treatments over time. This trial was designed to find new options for patients whose cancer no longer responds to existing therapies.
Participants received injections of the medication under the skin, starting with weekly injections for 8 weeks, then gradually spacing them out to every 2 weeks and then every 4 weeks. The trial lasted up to 42 months total, with participants continuing treatment until their cancer progressed, they experienced unacceptable side effects, or they chose to withdraw. Participants also had regular blood tests and visits to monitor how well the medication was working and check for side effects.
AI-generated summary from trial data · Oct 11, 2026 · Not medical advice
United States